NASDAQ:XFOR

X4 Pharmaceuticals Stock Insider Trading

etoro logo Buy XFOR
*Your capital is at risk
$3.97
-0.0700 (-1.73%)
At Close: Jun 03, 2026

X4 Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 95.45. In total, the insiders bought 31.82M and sold 1.12M XFOR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
95.45
Buy 31.82M shares
Sell 1.12M shares
81% Buy Activity
Negligible or No Correlation
Sell Signal Low Confidence
May 12, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 95.45.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jan 23, 2025
Buy
Common Stock
A-Award
Ragan Paula
President And CEO
CEO / President 169 940
Value: $2.64M
Jan 23, 2025
Buy
Common Stock
A-Award
Mostafa Adam S.
Chief Financial Officer
C-Suite Officer 74 773
Value: $1.16M
Jan 23, 2025
Buy
Common Stock
A-Award
Baldry Mark
Chief Commercial Officer
Officer 74 773
Value: $1.16M
Jan 23, 2025
Buy
Common Stock
A-Award
Dibiase Mary
Chief Operating Officer
C-Suite Officer 61 178
Value: $950.1K
Jan 23, 2025
Buy
Common Stock
A-Award
Arbet-engels Christophe
Chief Medical Officer
Officer 25 831
Value: $401.2K
Jan 23, 2025
Buy
Common Stock
A-Award
Arbet-engels Christophe
Chief Medical Officer
Officer 25 831
Value: $401.2K
Jan 23, 2025
Buy
Common Stock
A-Award
Dibiase Mary
Chief Operating Officer
C-Suite Officer 61 178
Value: $950.1K
Jan 23, 2025
Buy
Common Stock
A-Award
Baldry Mark
Chief Commercial Officer
Officer 74 773
Value: $1.16M
Jan 23, 2025
Buy
Common Stock
A-Award
Mostafa Adam S.
Chief Financial Officer
C-Suite Officer 74 773
Value: $1.16M
Jan 23, 2025
Buy
Common Stock
A-Award
Ragan Paula
President And CEO
CEO / President 169 940
Value: $2.64M
Nov 15, 2024
Buy
Common Stock
P-Purchase
Baldry Mark
Chief Commercial Officer
Officer 13 404
Value: $5K
Nov 15, 2024
Buy
Common Stock
P-Purchase
Baldry Mark
Chief Commercial Officer
Officer 13 404
Value: $5K
Nov 15, 2024
Sell
Common Stock
S-Sale
Ragan Paula
President And CEO
CEO / President 31 897
Value: $12.6K
Nov 15, 2024
Sell
Common Stock
S-Sale
Ragan Paula
President And CEO
CEO / President 31 897
Value: $12.6K
Oct 15, 2024
Sell
Common Stock
S-Sale
Ragan Paula
President And CEO
CEO / President 31 897
Value: $17.9K
Oct 15, 2024
Sell
Common Stock
S-Sale
Ragan Paula
President And CEO
CEO / President 31 897
Value: $17.9K
Oct 07, 2024
Sell
Common Stock
S-Sale
Dibiase Mary
Chief Operating Officer
C-Suite Officer 67 695
Value: $38.3K
Oct 07, 2024
Sell
Common Stock
S-Sale
Ragan Paula
President And CEO
CEO / President 239 436
Value: $131.5K
Oct 07, 2024
Sell
Common Stock
S-Sale
Baldry Mark
Chief Commercial Officer
Officer 11 127
Value: $7K
Oct 07, 2024
Sell
Common Stock
S-Sale
Mostafa Adam S.
Chief Financial Officer
C-Suite Officer 230 645
Value: $126.9K
Oct 04, 2024
Buy
Common Stock
A-Award
Dibiase Mary
Chief Operating Officer
C-Suite Officer 230 645
Value: $4.30M
Oct 04, 2024
Buy
Common Stock
A-Award
Ragan Paula
President And CEO
CEO / President 532 081
Value: $9.92M
Oct 04, 2024
Buy
Common Stock
A-Award
Baldry Mark
Chief Commercial Officer
Officer 34 946
Value: $651.4K
May 17, 2024
Buy
Common Stock
P-Purchase
Baldry Mark
Chief Commercial Officer
Officer 21 646
Value: $14.7K
May 17, 2024
Buy
Common Stock
P-Purchase
Baldry Mark
Chief Commercial Officer
Officer 21 646
Value: $14.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT X4 PHARMACEUTICALS INC.
X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and my...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE